Mersana Therapeutics reports Q2 EPS ($4.87), consensus ($4.25)

Reports Q2 revenue $3.056M, consensus $6.06M. “During the second quarter, we were excited to have Emi-Le clinical data presented in oral sessions at both ASCO 2025 and ESMO Breast Cancer 2025. These presentations highlighted Emi-Le’s encouraging clinical activity in patients with TNBC post-topo-1 treatment and those with adenoid cystic carcinoma type 1 (ACC-1),” said Martin Huber, M.D., President and Chief Executive Officer of Mersana Therapeutics (MRSN). “Our team has continued to make important progress in recent months, as evidenced by the strong pace of enrollment in the two ongoing dose expansion cohorts in our Phase 1 clinical trial of Emi-Le. We look forward to reporting initial clinical data from these expansion cohorts later this year.”